$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Acne Vulgaris - Pipeline Review, H1 2017
[Report Updated: 09-05-2017]

Published by Global Markets Direct: 09 May 2017 | 53487 | In Stock
Related Topics: Acne , Dermatology , Healthcare

Introduction

Acne Vulgaris - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 21, 6, 1, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Acne Vulgaris - Pipeline Review, H1 2017 [Report Updated: 09-05-2017]

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 6

    Introduction 7

    Global Markets Direct Report Coverage 7

    Acne Vulgaris - Overview 8

    Acne Vulgaris - Therapeutics Development 9

    Pipeline Overview 9

    Pipeline by Companies 10

    Pipeline by Universities/Institutes 14

    Products under Development by Companies 15

    Products under Development by Universities/Institutes 19

    Acne Vulgaris - Therapeutics Assessment 20

    Assessment by Target 20

    Assessment by Mechanism of Action 23

    Assessment by Route of Administration 26

    Assessment by Molecule Type 28

    Acne Vulgaris - Companies Involved in Therapeutics Development 30

    3SBio Inc 30

    Allergan Plc 30

    Almirall SA 31

    Biomar Microbial Technologies 31

    BioPharmX Inc 32

    Braintree Laboratories Inc 32

    Brickell Biotech Inc 33

    Cassiopea SpA 33

    Cell Medica Ltd 34

    Cellceutix Corp 34

    Celtaxsys Inc 35

    Common Pharma Inc 35

    Cutanea Life Sciences Inc 36

    Dermira Inc 36

    ELORAC Inc 37

    Ensol Biosciences Inc 37

    Foamix Pharmaceuticals Ltd 38

    Galderma SA 38

    GlaxoSmithKline Plc 39

    Helix BioMedix Inc 39

    Hovione FarmaCiencia SA 40

    Lee's Pharmaceutical Holdings Ltd 40

    LEO Pharma A/S 41

    Novabiotics Ltd 41

    Novan Inc 42

    Novartis AG 42

    Paratek Pharmaceuticals Inc 43

    Pfizer Inc 43

    Phosphagenics Ltd 44

    Photocure ASA 44

    Promius Pharma LLC 45

    Provectus Biopharmaceuticals Inc 45

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 46

    Sol-Gel Technologies Ltd 46

    Sun Pharma Advanced Research Company Ltd 47

    Valeant Pharmaceuticals International Inc 47

    Vectura Group Plc 48

    Vyome Biosciences Pvt Ltd 48

    XBiotech Inc 49

    Acne Vulgaris - Drug Profiles 50

    (adapalene + clindamycin hydrochloride) - Drug Profile 50

    (benzoyl peroxide + tretinoin) - Drug Profile 51

    (clindamycin phosphate + tretinoin) - Drug Profile 52

    acebilustat - Drug Profile 53

    Aczone Combo - Drug Profile 57

    aminolevulinic acid hydrochloride - Drug Profile 58

    AQ-401 - Drug Profile 59

    B-244 - Drug Profile 60

    BBI-3000 - Drug Profile 62

    benzoyl peroxide - Drug Profile 63

    BLI-1100 - Drug Profile 64

    brilacidin tetrahydrochloride - Drug Profile 65

    carbamide peroxide - Drug Profile 76

    CB-0301 - Drug Profile 77

    CB-0601 - Drug Profile 80

    CJM-112 - Drug Profile 81

    CLS-007 - Drug Profile 82

    dapsone - Drug Profile 83

    DFD-10 - Drug Profile 84

    DLX-2323 - Drug Profile 85

    DLX-2681 - Drug Profile 86

    DMT-210 - Drug Profile 87

    DMT-310 - Drug Profile 88

    DX-0385 - Drug Profile 89

    finasteride - Drug Profile 90

    FMX-101 - Drug Profile 91

    GSK-1940029 - Drug Profile 94

    HB-1345 - Drug Profile 95

    Hesed-4000 - Drug Profile 96

    IB-07A037 - Drug Profile 97

    IDP-120 - Drug Profile 98

    IDP-121 - Drug Profile 99

    IDP-123 - Drug Profile 100

    IDP-126 - Drug Profile 101

    IDP-129 - Drug Profile 102

    IDP-130 - Drug Profile 103

    ingenol disoxate - Drug Profile 104

    ivermectin - Drug Profile 106

    K-1032 - Drug Profile 107

    LTA-001 - Drug Profile 108

    methyl aminolevulinate hydrochloride - Drug Profile 109

    minocycline - Drug Profile 111

    minocycline - Drug Profile 112

    minocycline hydrochloride - Drug Profile 116

    MTC-896 - Drug Profile 117

    olumacostat glasaretil - Drug Profile 119

    omiganan pentahydrochloride - Drug Profile 124

    Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 126

    PF-06423264 - Drug Profile 127

    PH-10 - Drug Profile 128

    RA-18C3 - Drug Profile 131

    sarecycline hydrochloride - Drug Profile 133

    SB-204 - Drug Profile 135

    SKP-026 - Drug Profile 140

    Small Molecule for Acne and Skin Inflammation - Drug Profile 141

    Small Molecule to Agonise NR1C3 for Acne Vulgaris - Drug Profile 142

    Small Molecules for Acne Vulgaris - Drug Profile 143

    Synthetic Peptide for Acne Vulgaris - Drug Profile 144

    Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile 145

    tazarotene - Drug Profile 146

    tretinoin - Drug Profile 147

    tretinoin - Drug Profile 149

    trifarotene - Drug Profile 150

    Vaccine for Acne Vulgaris - Drug Profile 152

    VB-1953 - Drug Profile 153

    Acne Vulgaris - Dormant Projects 154

    Acne Vulgaris - Discontinued Products 159

    Acne Vulgaris - Product Development Milestones 160

    Featured News & Press Releases 160

    Appendix 171

    Methodology 171

    Coverage 171

    Secondary Research 171

    Primary Research 171

    Expert Panel Validation 171

    Contact Us 171

    Disclaimer 172

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

53487 | GMDHC9230IDB

Number of Pages

177

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Acne Vulgaris Global Clinical Trials Review, H2, 2018
Acne Vulgaris Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, “Acn...
25 Oct 2018 by Global Data USD $2,500 More Info
Acne And Related Disorders Global Clinical Trials Review, H2, 2018
Acne And Related Disorders Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial...
25 Oct 2018 by Global Data USD $2,500 More Info
Global Acne Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Acne Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Acne Vulgaris Global Clinical Trials Review, H2, 2016
Acne Vulgaris Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Acn...
27 Jul 2016 by Global Data USD $2,500 More Info
Acne Vulgaris Global Clinical Trials Review, H2, 2016
Acne Vulgaris Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Acn...
27 Jul 2016 by Global Data USD $2,500 More Info
Acne Vulgaris Global Clinical Trials Review, H1, 2016
Acne Vulgaris Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Acn...
15 Apr 2016 by Global Data USD $2,500 More Info
Acne Vulgaris Global Clinical Trials Review, H1, 2016
Acne Vulgaris Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Acn...
15 Apr 2016 by Global Data USD $2,500 More Info
Acne And Related Disorders Global Clinical Trials Review, H2, 2015
Acne And Related Disorders Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial...
30 Nov 2015 by Global Data USD $2,500 More Info
Global Acne Treatment Market: Trends and Opportunities (2014-2019)
Scope of the ReportThe report titled “Global Acne Treatment Market: Trends and Opportunities (2014-2...
01 Jan 2015 by Daedal Research USD $800 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Acne Vulgaris - Pipeline Review, H1 2017 [Report Updated: 09-05-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)